Theaflavin 3,3'-digallate
A catechin.
C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC4=C(C(=C(C=C4[C@@H]5[C@@H](CC6=C(C=C(C=C6O5)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)C(=O)C(=C3)O)OC(=O)C8=CC(=C(C(=C8)O)O)O
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease
3CLpro Small molecule In silico |
in silico | 3.22 | Predicted to inhibit the SARS-CoV-2 3C-like protease. |
Sep/08/2020 |
|
A molecular docking study of EGCG and theaflavin digallate with the druggable targets of SARS-CoV-2
Small molecule In silico |
in silico | 3.43 | Predicted to target multiple SARS-CoV-2 factors. |
Nov/23/2020 |
|
Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study
3CLpro PapainLpro RdRpol Small molecule In silico |
in silico | 3.22 | Predicted to inhibit SARS-CoV-2 RNA-dependent RNA polymerase. |
Mar/10/2021 |
